Correct misiu. Here is the portion of the 30 September CC that discusses the CROI abstract submissions and the 'stunning' results that will be included in the BLA submission to the FDA (I tried to correct some of the transcript translation errors from the original transcript trding posted):

Quote:

---

12:24 in regards to HIV we also have something
12:26 else to tell everyone. The CROI is
12:29 conference of retroviruses and
12:31 opportunistic the infection is the most
12:33 powerful conference for HIV. We
12:37 participated in that in the past but
12:39 this time for CROI we did not submit
12:43 abstract directly but other people are
12:45 now noticing the potential of leronlimab
12:48 and they have. The first abstract was
12:51 for PrEP, prevention that was submitted
12:55 Dr. Jonas Sacha some very strong result
12:57 and the abstract has been submitted to
13:00 CROI as of the deadline of September 26.
13:03 November 15 the results of acceptance
13:05 we'll be announced. We expect major media
13:08 to cover this presentation as prevention in
13:11 HIV space is a very important and hot
13:14 topic. The second abstract is from Dr.
13:17 Stefano Rusconi from University of
13:20 Milan Italy. Very exciting results. We
13:24 have given permission to them to publish
13:26 the results of our molecule in CROI as
13:30 we agreed the results are stunning. We
13:33 can't talk about these results, but I can
13:35 tell you we are so impressed by them
13:38 that we are including them in our BLA
13:41 submission to the FDA.

---

Complete 30 September CC Transcript Post: https://investorshangout.com/post/view?id=5553544

30 September CC Link: https://78449.themediaframe.com/dataconf/prod...ndexl.html